BIOREGENX, INC. 10-K

 false 2023 FY 0001593184

 2023-06-30

 2024-04-11

 us-gaap: SeriesAPreferredStockMember

 us-gaap: SeriesAPreferredStockMember

 us-gaap: SeriesBPreferredStockMember

 us-gaap: SeriesBPreferredStockMember

 2020-11-25

 FDIT:EIDLMember

 2020-07-19
 2020-07-20

 FDIT:EIDLMember

 2021-07-16
 2021-07-17

 FDIT:SBALoan2020Member

 FDIT:SBALoan2020Member

 FDIT:SBALoan2021Member

 FDIT:SBALoan2021Member

 FDIT:ClassworxMember

 FDIT:ClassworxMember

 FDIT:ThomasPowersMember

 FDIT:ThomasPowersMember

 2023-03-30
 2023-03-31

 FDIT:TransworldNewsMember

 FDIT:TransworldNewsMember

 FDIT:TransworldNewsMember

 FDIT:ThomasPowersMember

 2023-10-01

 UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C. 20549

 FORM 10-K

 ANNUAL REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934

 For the fiscal year ended: December 31, 2023

 OR

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934

 For the transition period from _____________to

 Commission file number: 000-1593184

 (Exact name of Company in its charter)

 Nevada

 30-1912453

 (State or other jurisdiction of incorporation or organization)

 (I.R.S. Employer Identification)

 7407 Ziegler Road

 Chattanooga, TN, 37421

 (Address of principal executive offices, including
zip code)

 Registrant's Telephone number, including area code:
 (866) 770-4067

 Securities registered pursuant to Section 12(b)
of the Act: None

 Securities registered pursuant to Section 12(g)
of the Act: Common Stock, $0.001 par value

 Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No

 Indicate by check mark if the registrant is not
required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes No

(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the preceding 12 months (or
such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for at
least the part 90 days.

 Yes No

has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (section 232.406 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files). Yes No

is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company.

 Large accelerated filer

 Accelerated filer

 Non-accelerated filer

 Smaller reporting company

 Emerging growth company

 If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.

has filed a report on and attestation to its management's assessment on the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered firm that prepared or issued its audit
report

 If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements.

 Indicate by check mark whether any of those error corrections are restatements
that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during
the relevant recovery period pursuant to §240.10D-1(b).

is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 State the aggregate market value of the voting
and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the
average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second
fiscal quarter. The market value of the registrant's voting $0.001 par value common stock held by non-affiliates of the registrant
on June 30, 2023, was approximately $ 4,244,930.

 Indicate the number of shares outstanding of each
of the registrant's classes of common stock, as of the latest practicable date. The number of shares outstanding of the registrant's
only class of common stock, as of April 11, 2024 was 956,630,100 shares of its $0.001 par value common stock.

 No documents are incorporated into the text by
reference.

 BioRegenx, Inc. (formerly Findit, Inc.)

 Form 10-K

 For the Fiscal Year Ended December 31, 2023

 Page

 Item 1. Business

 Item 1A. Risk Factors

 Item 1B. Unresolved staff comments

 Item 2. Properties

 Item 3. Legal Proceedings

 Item 4. Mine Safety Disclosures

 Item 5. Market for Company's Common Equity, Related Stockholders Matters and Issuer Purchases of Equity Securities

 Item 6. Selected Financial Data

 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

 Item 7A. Quantitative and Qualitative Disclosures about Market Risk

 Item 8. Financial Statements and Supplementary Data

 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 Item 9A. Controls and Procedures

 Item 9B. Other Information

 Item 10. Directors, Executive Officers and Corporate Governance

 Item 11. Executive Compensation

 Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 Item 13. Certain Relationships and Related Transactions, and Director Independence

 Item 14. Principal Accountant Fees and Services

 Item 15. Exhibits, Financial Statement Schedules

 Signatures

 i

 ITEM 1. BUSINESS

 BioRegenx, Inc. (formerly Findit, Inc.) was originally
incorporated on December 23, 1998 in the state of Nevada. Effective March 8, 2024, BioRegenx, Inc., a Nevada corporation was merged into
Findit, Inc. resulting in a change of control. Pursuant to the terms of the merger, the name of the company was changed to BioRegenx,
Inc. (the "Company").

 Pursuant to the merger,
all of the issued and outstanding BioRegenx, Inc. common and preferred shares were exchanged for 851,977,296 common shares and 3,800 Series
A preferred shares of the Company which represented 90.0% of the voting securities of the Company. Concurrently, holder(s) of the Company's
Series A and Series B preferred shares retired all of their Series A and Series B preferred shares back into the treasury. The retired
Series A and Series B preferred shares represented a voting control of 98.47% of the Company. Simultaneously, the majority shareholders
retired a total of 172,197,602 common shares. The exchange value of the Company's stock was the average closing price of the Company
for the month of November 2022.

 As soon as practical
after the merger, both parties agreed to the implementation of up to a 1 for 25 reverse split of the Company's common and preferred stock
to improve the Company's ability to attract institutional investors and analysts as well as to graduate to a senior exchange (OTCQB, NASDAQ).

 Operating Subsidiaries

 DocSun BioMedical Holdings, Inc.

 On January 11, 2024, pursuant to a Securities
Exchange Agreement effective November 15, 2023 and an Addendum to the Securities Exchange Agreement dated December 5, 2023, BioRegenx
acquired DocSun Biomedical Holdings, Inc. Pursuant to the Securities Exchange Agreement, BioRegenx acquired all of the issued and outstanding
securities of DocSun in exchange for 4,800,000 BioRegenx common shares.

 Technology

 DocSun combines three proven technologies
in the DocSun Artificial Intelligence (AI) Engine. The DocSun AI Engine integrates advanced ballistocardiography, which can detect an
individual's heartbeat without touch, and photoplethysmography, a method that uses light to track the flow of blood. These methodologies
are further enriched with the decoding capabilities of optical coherence tomography, a technique that creates detailed images of structures
inside the body. This combination is meticulously designed to harness the power of artificial intelligence for accurate vital sign estimation.

 By deploying a strategic facial scanning technique,
the engine captures and analyzes nuanced physiological signals. This not only facilitates the precise extraction of vital signs but also
ensures a non-invasive, user-friendly approach to health monitoring, embodying a confluence of technology and practical applicability
in the realm of remote health diagnostics.

 Sales
and Marketing

 DocSun's engineering
team is actively engaged in installing new hardware and coding software to enhance AI capabilities, paving the way for future growth opportunities.

 Contracts

 DocSun entered into a technical services agreement
with a large software technology company to provide technical services in China, Hong Kong and Macao. This agreement involves supplying
DocSun's AI Engine technology to the distributor targeting multiple sectors, including the latest release of DocSun's Software Development
Kit (SDK). Initial revenues stem from the testing of DocSun's SDK in fleet and electric vehicles (EV's) amongst other applications, with
commercialization slated to begin in late third quarter or early fourth quarter. As per the agreement terms, DocSun will receive a signing
fee of $200,000 (payable over ten months) and will receive a 40% of all the revenue generated including 40% of the $10 per vehicle license
fee from the EV automotive manufacturer. The term of the agreement commences upon receipt of the first installment of the signing fee
and is for a period of five years.

 On October 16, 2023, DocSun entered into a License
Agreement with NuLife Sciences, Inc. under which it granted NuLife a world-wide non-exclusive license to use its technology. DocSun shall
receive a license fee of $3.50 per subscriber. The first demo scan is complimentary for each unique email address. The agreement will
continue for an initial period of three years and will automatically renew for periods of three years unless either party gives not of
non-renewal to the other party at least thirty days prior to the end of any three year term.

 Additionally, under the License Agreement, NuLife
paid DocSun $155,000 for the development costs related to the development of TruScan. Ai mobile app/website. The development encompasses:

 (a) Incorporating DocSun's
AI Engine: A pivotal integration, enabling the platform to deliver 21 critical health indications, ensuring comprehensive and accurate
health monitoring.

 (b) User-Experience (UX) Design:
Seamless Navigation, Personalized Monitoring

 DocSun is sculpting an intuitive and accessible
interface, meticulously designed to cater to users across all demographics, ensuring effortless navigation and utilization of the platform.
DocSun's focus is to empower users with the ability to:

 (c) Monitor Holistically:
View and analyze their health metrics not just as standalone figures, but as a comprehensive, easy-to-understand narrative, whether they
choose to explore it daily, monthly, or across custom-defined periods.

 (d) Historical Wellness Tracking:
A dedicated section for users to effortlessly scroll through their past wellness scans, juxtaposed with the latest data, enabling them
to observe, compare, and comprehend their wellness journey over time.

 (e) Engaging Visuals: Employing
vibrant, yet non-intrusive visuals to represent data, ensuring users can at a glance, comprehend their health status and any fluctuations
therein.

 (f) Personalized Alerts: Tailoring
notifications and alerts to keep users abreast of their wellness, gently nudging them towards maintaining or enhancing their health metrics
and potential products.

 Through these, DocSun's aim is to not just
provide data but to enhance user engagement, making health monitoring not a task, but an engaging, insightful experience.

 (g) Integration with VitalWellness
mobile app: A crucial phase of the development involves seamless integration into the VitalWellness mobile app, ensuring that the rich
functionalities and health indications of TruScan. Ai are accessible to users across both Apple and Android platforms. This integration
is not just about data sharing but ensuring that user experiences are unified and coherent across platforms, providing a consistent and
reliable health monitoring experience.

 Revenues

 DocSun will derive revenues under the terms of
the distribution agreement described above and from the licensing of its technology.

 Microvascular Health
Solutions LLC

 MVHS specializes in research, product development,
sales, and education, notably producing the patented Endocalyx Pro dietary supplement. MVHS also manufactures and distributes the
patented GlycoCheck software and Class 1 medical device. Presently, MVHS actively participates in multiple double-blind placebo
studies worldwide, exploring the impact of Endocalyx Pro on various health conditions while maintaining compliance with GMP regulations.

 Patents

 Endocalyx Pro patents:

 United States: US9943572

 Europe: EP3280423

 China: ZL 201680033444.2

 Japan: 6518796

 South Korea: 10-1972691

 Canada (Pending): 3020277

 Products

 Endocalyx Pro.
Endocalyx Pro is a dietary supplement targeting microvascular capillary health.

 Production.
Our supplement is produced by a fully accredited and certified manufacturing facility. Our source has provided outstanding contract manufacturing,
formulation expertise, and custom finishing and packaging to the dietary supplement industry. They specialize in encapsulation, tablet
compression, powder blending and filling, and product development. The company is currently in discussions with other fully accredited
and certified manufacturing facilities for future expansion.

 Distribution.
Distribution is handled at NuLife Sciences in Chattanooga, TN and Midstates Fulfillment, Aberdeen, SD.

 Sales
and marketing. The supplement has achieved monthly sales figures that have demonstrated consistent growth. In 2024, the Company is intensifying
its sales and marketing efforts to further boost sales, with GlycoCheck's integration into the market expected to synergistically enhance
Endocalyx Pro sales.

 Additional supplements.
MVHS offers a range of supplements through its wholly-owned subsidiary, MyBodyRx, LLC.

 Wholly Owned Subsidiary

 MyBodyRx is a manufacturing, sales and
product development company that produces dietary supplements that complement and work synergistically with the patented and clinically
tested Endocalyx Pro product to support and improve healthy aging and increase longevity.

 MyBodyRx is produced by a fully accredited
and certified manufacturing facility. Our source has provided outstanding contract manufacturing, formulation expertise, and custom finishing
and packaging to the dietary supplement industry. They specialize in encapsulation, tablet compression, powder blending and filling, and
product development.

 Contracts

 Since 2020, MVHS has worked with Omni Imaging,
Inc., a research and development company which focuses on the innovation and renovation of imaging technologies specifically on medical,
consumer and industrial applications. MVHS and Omni are jointly developing and producing the CapiVision cameras for GlycoCheck.
MVHS has filed one pending patent relating to the camera.

 Revenues

 MVHS derives revenue from sales of GlycoCheck
systems to academic research hospitals and groups, private medical practices, pharmacies, dentists, and wellness practitioners. Income
is also derived from transfer sales of GlycoCheck with NuLife Sciences. Endocalyx Pro dietary supplements are sold
to doctors, patients, and consumers. In addition, revenue is derived from sales of Endocalyx Pro to medical wholesalers and resellers.
Endocalyx Pro is produced and sold at transfer pricing as an intercompany transaction with NuLife Sciences.

 Additionally,
in December 2023, MVHS unveiled the updated version of its pioneering GlycoCheck device, boasting significant hardware and software
enhancements. MVHS commenced sales by fulfilling pre-orders and continues to deliver on new sales, with GlycoCheck system packages priced
between $22,000 to $32,000, generating monthly recurring revenue based on tests performed. Favorable financing options have been secured
for GlycoCheck customers, ensuring accessibility and affordability.

 MyBodyRx derives revenue from supplements that
are designed to be synergistic with Endocalyx Pro TM. These products are produced and sold at transfer pricing as an intercompany
transaction with NuLife Sciences TM.

 NuLife Sciences,
Inc.

 NuLife functions as a marketing and distribution
enterprise, aiming to redefine health and longevity by leveraging advanced technologies. NuLife exclusively markets the MyBodyRx supplement
line, that includes our patented product Endocalyx Pro and also markets GlycoCheck along with other medical and wellness
devices for overall improved health and wellness outcomes.

 In addition to the line of the MyBodyRx nutraceutical
products offered, NuLife markets hydrogen water products, medical and wellness devices such as Pulsed Electro-Magnetic Field devices and
StimaWELL, a class II Electronic Muscle Stimulation therapy device through a network of independent affiliates, practitioners, and customers.
NuLife is currently developing a wellness app with a technology company which will provide DNA and epigenetics testing products and services.
These therapies cater to a wide array of health indications, promoting overall well-being.

 TruScan. Ai mobile app/website.

 NuLife is working in collaboration with DocSun
to develop its TruScan. AI mobile app integrating DocSun's AI engine. The platform is designed to seamlessly integrate additional
health indications as they are developed and released by Licensor in the future. TruScan. Ai mobile app will incorporate health indicators
in the following four sectors: vitals, nutrients, wellness and skin health metrics. The TruScan. Ai mobile app is scheduled for release
in the second quarter of 2024.

 VitalWellness mobile app

 NuLife is also in development of VitalWellness
app to be call VitalWellness that will merge its DNA and epigenetics platform with the TruScan. Ai technology.

 Contracts

 As described above under DocSun, NuLife entered
into a license agreement with DocSun to use the DocSun technology.

 Sales and Marketing

 NuLife currently utilizes a network of active
independent brand partners in addition to both retail and auto-ship customers.

 Revenue

 Revenue is generated from the sale of goods and
services to doctors, healthcare practitioners, patients, consumers and wholesale distribution.

 Findit Ai Connect, Inc.

 Simultaneously with the closing of the merger,
the Registrant created Findit Ai Connect, Inc. (Findit Ai), a wholly owned subsidiary and capitalized the subsidiary with the Findit pre-merger
assets and liabilities. Findit Ai owns Findit.com and the Findit App that is available in Android and IOS through the Google Play Store
and the Apple App store. Findit.com and the Findit App operate as a Social Media Content Management Platform, that includes its own interactive
search engine. Members can utilize Findit Ai search to submit URLs they want Findit Ai to index in Findit search results. Nonmembers can
come to Findit Ai and enter search queries, Findit Ai returns matching search results from content posted in Findit Ai along with outside
web pages that have been submitted.

 Patents, Trademarks Licenses
and Other Intellectual Property

 We own trademarks in "Findit" and "Findit.com".

 Products
and Services

 Both Findit.com, the
website and the Findit App are accessible to anyone, this means you do not need to be a member of Findit Ai to view or search content
posted in Findit Ai. Anyone that wants to have content indexed in Findit Ai search or viewed by visitors on Findit Ai can do so by creating
a free account and posting their content to the various verticals Findit Ai offers.

 Claim
Your Name – Claim Your Name is a tool offered on Findit Ai to members that want to have a specific URL extension after Findit.com
can purchase these URLs on Findit Ai. The purchase price for one is currently $9.95. The price has varied over several years. Members
that run paid for online marketing campaigns with Findit Ai often get multiple Findit Ai URLs as part of their campaign budget. The Claim
Your Name feature does provide members that have specific words in their extension URLs do get preferential indexing in the Company's
search engine.

 Search
Engine Optimization – Findit Ai provides online Search Engine Optimization services also known as SEO. Findit Ai offers these
services to clients to that are seeking to index better in search engines that include but are not limited to Findit, Google, Yahoo
and Bing. SEO services are offered from Findit Ai as a one-time payment for a specific task or on an ongoing basis, typically paid
for monthly.

 Content
Campaigns – Findit Ai offers businesses and individuals online content campaigns. These campaigns provide Findit Ai clients/customers
with content that the Findit Ai staff creates and posts the content created within the Findit Ai members account that hired Findit Ai.
This content can include written words, videos, pictures, audio and back links. The purpose of these types of campaigns is to provide
the Findit Ai client with additional content for Findit Ai and outside search engines that include but are not limited to Google, Yahoo
and Bings to index and increase the clients overall online web presence organically. The content created and posted to Findit Ai can
also be shared to outside websites that are typically other social networking sites. These social sites are Facebook, Twitter, Pinterest,
Linked In, Instagram (from the APP to IM) along with approximately 80 other social and bookmarking sites. The share function is on the
Findit.com website and is provided through Share This. Content campaigns typically are offered in 30 day intervals and clients automatically
renew. At this time Findit Ai does not lock clients in for more than 30 days and offer this service based on the number of pieces of
content created. The content created is typically done over 30 days but can be done in shorter or longer period of time depending on
the clients' instructions.

 Social
Media Campaigns– Findit Ai offers clients Social Media campaign services as a paid for service. These services are offered
to clients that are typically seeking more engagement from individuals on social networking sites. Clients are looking to build brand
awareness, more friends and or followers, receive comments on posts, likes and or other reactions Members of Findit Ai can also use Findit
Ai themselves to run social media campaigns without paying Findit Ai any monies. Findit Ai does offer some paid for tools to enhance
a social media campaign that the Findit member can opt in and pay for. This includes a promoted post feature. A promoted post is currently
offered at $19.00 per promoted post. A post that is promoted is created in the Findit Right Now status update section of Findit.com or
from the Findit App. The member can select to have the post promoted for $19.00. Once a member selects to have the post promoted a Findit
Ai social media person will take that Right Now post and share it through Findit Ai's social networking accounts. These accounts
include but are not limited to Google My Business, Facebook, Pinterest, Twitter and Linked In.

 Web
Design – Findit Ai offers web design services. Findit Ai tends to develop and build sites using Wordpress. Sites are typically
built for existing clients that are utilizing the Company's services on a monthly basis to enhance their online presence. Findit
Ai's web design services are not advertised on the website as a service. The web design service is typically offered to an existing
client that may benefit from a newer version website. Findit Ai provides members the ability to post content and once it is posted they
have the option to share the content they posted to outside websites that include but are not limited to Facebook, Pinterest, Linked In,
Twitter and more. In addition to the member who posts the content, anyone who views the content also has the ability to share the content
to their social accounts. Once content is posted in Findit, the content gets indexed in Findit Search results.

 With Findit Ai's
open platform for anyone to submit URLs that they want to have indexed in Findit Ai along with posting status updates through Right Now.
Status Updates posted in Findit Ai can be crawled by outside search engines to assist in additional organic indexing. All post can be
shared to other social and bookmarking sites.

 Findit Ai also provides
news and press release distribution services. Findit Ai has also developed a social networking App that is available to Android and iOS
devices. Findit Ai is focused on the development of monetized internet-based web and app products that increase brand awareness for both
private and public companies along with individuals, entrepreneurs and artists.

 Apple
IOS is reporting 96 downloads, 2.7k impressions in 2022 and an additional 16 downloads, 1.7k impressions in 2023. Findit Ai downloads
according to Google Android Playstore are currently unknown but management is of the opinion that the number would not be significantly
different than the iOS downloads and usage. These numbers are provided from Apple through our accounts. A Findit member is someone who
has created a Findit account by creating a username and password on the platform. We do not determine, at this time, which members are
active and which members are inactive. We currently do not have code written that provides these analytics. We intend, as funds allow,
to bring on additional developers that will be able to write code that will provide this data.

 Revenues

 We currently monetize
Findit in several ways, through online content marketing campaigns, offering online products and tools through Findit.com.

 Market Size

 Overview

 The global health market, valued at over $4 trillion,
undergoes transformative shifts, including the rise of remote health monitoring and proactive healthcare solutions. The Company actively
addresses this market through innovative technologies and strategic initiatives.

 As of the latest available market data, the Company
operates at the forefront of the expansive anti-aging, health, and longevity markets, which collectively represent a multi-trillion-dollar
industry. The following analysis integrates recent market figures, trends, and opportunities in each sector, emphasizing the substantial
growth potential. Additionally, insights into DocSun's AI technology and its applications in Telehealth, Automotive EV cars, and the broader
transportation market are detailed.

 Trends and Growth Potential

 Telehealth and Remote Monitoring: The industry
experiences a notable shift towards remote health monitoring and telehealth services, valued at approximately $176 billion.

 Preventive Healthcare: Increasing awareness
prompts a transition from reactive to proactive healthcare, creating opportunities for innovative solutions.

 Market Strategy

 The Company and its subsidiaries adopt a comprehensive
approach encompassing business-to-business (B2B) and business-to-consumer (B2C) strategies. These strategies are tailored for targeted
markets, including academic research hospitals, medical professionals, and direct-to-consumer initiatives.

 Marketing Strategies:

 Leverage existing relationships with the healthcare
practitioner community through training, seminars, webinars, and other industry events.

 Continue engaging with researchers to perform
tests using GlycoCheck to link microvascular health to conditions and disease.

 Continue engaging with researchers on double-blind
placebo studies of Endocalyx Pro

 DocSun AI technology as cutting edge solutions
in healthcare, transportation, insurance

 Use affiliate marketing programs where the company
collaborates with nutritionists and wellness influencers for synergistic formulas.

 DOCSUN AI Engine: Engage healthcare influencers
and professionals through gig economy channels, highlighting the AI engine's capabilities. Promote the product through webinars and social
media campaigns.

 TruScan. Ai Integration in the VitalWellness
App: Leverage gig economy influencers to showcase the app's convenience and accuracy through personal testimonials and user stories.

 Sales and Distribution:

 Continued sales to academic researchers worldwide
for validation of the science

 Expand sales to healthcare facilities, diagnostic
labs, and emergency room care

 Direct-to-consumer sales

 Sales through supplement wholesale distribution

 Sales through practitioner clinic locations

 Partnerships with wellness centers and genetic
testing providers for extended accessibility.

 B2B sales for the DOCSUN AI Engine to healthcare
institutions, facilitated by gig economy influencers.

 B2C distribution for the VitalWellness App through
online app stores.

 Pricing Strategies and
Positioning:

 Recurring sales on Software as a Service tests
performed using GlycoCheck

 Recurring sales from practitioner recommendations,
and direct-to-consumer sales, of supplement products

 Synergistic supplement product extensions

 Enable wholesalers, influencers, to make a profit
on sales for their continued engagement

 Pricing Strategies and Positioning:

 DOCSUN AI Engine positioned as a premium solution
for healthcare professionals.

 VitalWellness App competitively priced for widespread
consumer adoption within gig economy channels.

 Competition

 There is huge competition in the anti-aging market
due to the presence of many domestic and international market players. Most of the market players are adopting various growth strategies,
such as acquisitions, partnerships, and new product launches, in order to secure their position in the market.

 (

 All aspects of the health, nutritional, supplements
and medical devices business are highly competitive. The firms that our subsidiaries compete with include large well-known firms who have
substantially greater financial and personnel resources. Our subsidiaries compete for business on the basis of our experience in the industry,
their ability to execute business transactions and the strength of our relationships with their clients. Intense competition could negatively
affect their operations.

 We face significant competition
in almost every aspect of our business, including from companies such as Google, Microsoft, Facebook, Instagram, Twitter, Zillow and other
press release distribution services. These competitors offer a variety of Internet products, services, content, and online advertising
offerings, as well as from mobile devices that offer products and services that may compete with specific Findit features. We also face
competition from traditional and online media businesses for content to be posted on the Findit Platform.

 We currently are not
running paid advertising campaigns on Findit, but we plan to in the future. When the Company does offer paid for advertising we expect
to face competition from these same companies. We compete broadly with Facebook, Instagram and Twitters social networking offerings along
with Google, Yahoo and Bing for search queries. As we introduce new products, as our existing products evolve, or as other companies introduce
new products and services, we may become subject to additional competition.

 Some of our current and
potential competitors have significantly greater resources and better competitive positions in certain markets than we do. These factors
may allow our competitors to respond more effectively than us to new or emerging technologies and changes in market requirements. Our
competitors may develop products, features, or services that are similar to ours or that achieve greater market acceptance, may undertake
more far-reaching and successful product development efforts or marketing campaigns, or may adopt more aggressive pricing policies. Certain
competitors, including Google, could use strong or dominant positions in one or more markets to gain competitive advantage against us
in creating a similar search feature that offers people the ability to submit web pages for indexing under various titles and descriptions.
Other social networking sites or sites that do not exist yet could create similar featured Findit offers to compete with our market share.
As a result, our competitors may acquire and engage users at the expense of the growth or engagement of our user base, which may negatively
affect our business and financial results.

 We believe that our ability
to compete effectively depends upon many factors both within and beyond our control, including:

 the usefulness, ease of use, performance, and reliability of our products compared to our competitors;

 the size and composition of our user base;

 the engagement of our users with our products;

 the timing and market acceptance of our products and our tools;

 our ability to monetize our products, including our ability to successfully monetize app usage;

 Competitors range from traditional healthcare
providers to emerging telehealth startups and health technology companies.

 Anti-Aging (in general): Key Competitors:

 Competition in this space remains fierce, encompassing
established skincare and wellness brands, alongside emerging players focusing on technology-driven anti-aging solutions.

 Industry Competition: The health and wellness sector is highly competitive, with potential challenges
in differentiating BioRegenx's products and services.

 Competitive Advantages

 Pricing Strategies and
Positioning:

 Synergistic formulas positioned competitively
for all channels

 Pricing Strategies and
Positioning:

 Maintain a competitive pricing strategy for
the VitalWellness App to encourage widespread adoption.

 VitalWellness App competitively priced for widespread
consumer adoption within gig economy channels.

 Operational Systems:

 We have developed cutting-edge operational systems
that enable us to provide high-quality products and services at a competitive cost. These systems include streamlined manufacturing processes,
efficient supply chain management, and advanced technologies for product development.

 Employees

 In addition to its respective officers, the Company
and its subsidiaries currently employ ten individuals, along with strategic outsourcing to keep resources focused where they are needed.

 Implications of Being an "Smaller Reporting
Company"

 Certain reduced reporting requirements and exemptions
are available to us due to the fact that we qualify as a "smaller reporting company" under SEC rules. For instance, smaller
reporting companies are not required to obtain an auditor attestation report regarding management's assessment of internal control
over financial reporting; are not required to provide a compensation discussion and analysis; are not required to a pay-for-performance
graph or CEO pay ratio disclosure; and may present only two years of audited financial statements and related MD&A disclosure. Investors
should be aware that we will be subject to the "Penny Stock" rules adopted by the Securities and Exchange Commission, which
regulate broker-dealer practices in connection with transactions in Penny Stocks. These regulations may have the effect of reducing the
level of trading activity, if any, in the secondary market for our stock, and investors in our common stock may find it difficult to sell
their shares.

 ITEM
1A. RISK FACTORS

 Not applicable to a smaller reporting
company.

 ITEM 1B. UNRESOLVED STAFF
COMMENTS

 Not applicable.

 ITEM 2. PROPERTIES

 The Company is a global company that takes advantage
of the ability to work remotely from many locations utilizing the latest video technology that has proven to be effective for businesses
during the Covid-19 pandemic. We were effectively working remotely for several years prior to the pandemic and consequently were not affected
by stay-at-home orders since early 2020.

 The Company is currently located at 7407 Ziegler
Rd., Chattanooga, Tennessee 3742. BioRegenx shares the Chattanooga offices with NuLife. The offices consist of 1,000 sq ft. leased on
a month to month basis with a monthly lease rate of $1,275. The lease payment is paid by NuLife. Additional facilities will be leased
as needed.

 ITEM 3. LEGAL PROCEEDINGS

 The Company may be involved in legal proceedings
in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. There
are no material pending legal proceedings.

 From time to time, we may become involved in various
lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties,
and an adverse result in these or other matters may arise from time to time that may harm our business.

 ITEM 4. MINE SAFETY DISCLOSURES

 None

 ITEM 5. MARKET FOR COMPANY'S COMMON EQUITY, RELATED STOCKHOLDER
MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 Item 5(a)

 a) Market Information. The
Company trades under the symbol FDIT on the OTC Markets Pink. The quotations represent inter-dealer prices without retail markup, markdown
or commission, and may not necessarily represent actual transactions.

 There have been a limited amount of trades of
the Company's stock since it was listed on the OTC Markets Pink there are no assurances that a market will ever develop for the
Company's stock.

 The following table sets forth the high and low
sales prices for our common stock, which has been listed on the OTC Markets Pink for all periods presented.

 Year Ended December 31, 2023

 High

 Low

 3/31/2023

 $
 0.08

 $
 0.06

 6/30/2023

 $
 0.06

 $
 0.06

 9/30/2023

 $
 0.04

 $
 0.04

 12/31/2023

 $
 0.03

 $
 0.02

 Year Ended December 31, 2022

 High

 Low

 3/31/2022

 $
 0.02

 $
 0.02

 6/30/2022

 $
 0.01

 $
 0.01

 9/30/2022

 $
 0.01

 $
 0.01

 12/31/2022

 $
 0.06

 $
 0.02

 b) Holders. On April
11, 2024, there were 298 shareholders of record of our common stock.

 c) Dividends. Holders of our
common stock are entitled to receive such dividends as may be declared by our board of directors. No dividends on our common stock have
ever been paid, and we do not anticipate that dividends will be paid on our common stock in the foreseeable future.

 d) Securities authorized for
issuance under equity compensation plans.

 There are no outstanding grants or rights or any
equity compensation plan in place.

 e) Performance graph. Not
applicable.

 f) Sale of unregistered securities.

 During the year ended December 31, 2023, the Company
issued 1,000,000 shares of common stock to non-affiliates for services. The shares were valued at $0.0816, the closing stock price on
the date of grant, for total non-cash compensation expense of $81,600. The securities were issued under Rule 4(a)(2) of the Securities
Act of 1933.

 On March 31, 2023, the Company issued
6,005,400 shares of common stock to Mr. Powers, for $28,270 of debt and $8,539 for expense reimbursement. The shares were valued at $0.0816,
the closing stock price on the date of grant, resulting in a loss on the issuance of $453,232.

 Subsequent to year end, pursuant to the merger,
on March 8, 2024, all of the issued and outstanding BioRegenx common and preferred shares were exchanged for 851,977,296 common shares
and 3,800 Series A preferred shares of the Registrant which represented 90.0% of the voting securities of the Registrant. Concurrently,
holder(s) of the Registrant's Series A and Series B preferred shares retired all of their Series A and Series B preferred shares
back into the treasury. The Series A and Series B preferred shares represented a voting control of 98.47% of the Company.

 Simultaneously, the majority shareholders retired
a total of 172,197,602 common shares. The exchange value of Company's stock was the average closing price of Company for the month
of November 2022. The securities were issued under Rule 506 of Regulation D of the Securities Act of 1933.

 ITEM 6. SELECTED FINANCIAL DATA

 Not applicable to a smaller reporting company.

 ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS

 Forward-looking Statements

 Statements in this Management's Discussion
and Analysis of Financial Condition and Results of Operation, as well as in certain other parts of this Annual report on Form 10-K (as
well as information included in oral statements or other written statements made or to be made by the Company) that look forward in time,
are forward-looking statements made pursuant to the safe harbor provisions of the Private Litigation Reform Act of 1995. Forward-looking
statements include statements concerning plans, objectives, goals, strategies, future events or performance, expectations, predictions,
and assumptions and other statements that are other than statements of historical facts. Although the Company believes such forward-looking
statements are reasonable, it can give no assurance that any forward-looking statements will prove to be correct. Such forward-looking
statements are subject to, and are qualified by, known and unknown risks, uncertainties and other factors that could cause actual results,
performance, or achievements to differ materially from those expressed or implied by those statements. These risks, uncertainties and
other factors include, but are not limited to the Company's ability to estimate the impact of competition and of industry consolidation
and risks, uncertainties and other factors set forth in the Company's filings with the Securities and Exchange Commission, including
without limitation to this Annual Report on Form 10-K.

 The Company undertakes no obligation to update
forward-looking statements to reflect events or circumstances occurring after the date of this Form 10-K.

 Results of Operations

received total revenues from Findit services of $22,243 with cost of goods sold of $0 resulting in a gross margin of $22,243. Comparatively,
for the year ended December 31, 2022, the Company received total revenues from Findit services of $42,159 with cost of goods sold to $0
resulting in a gross margin of 42,159.

incurred total operating expenses of $131,906 which consisted of advertising and marketing expenses of $245, amortization expense of $5,932,
professional fees of $7,080, programming fees of $700, web design and hosting expense of $18,095 and general and administrative expenses
of $18,254. Comparatively, for the year ended December 31, 2022, the Company incurred total operating expenses of $120,467 which consisted
of advertising, marketing and press release expenses of $6,043, amortization expense of $5,932, content writing of $21,750, professional
fees of $27,928, programming fees of $9,735, web design and hosting expense of $21,432 and general and administrative expenses of $27,647.

had a loss on conversion of debt-related party of $(453,232), unrealized loss on investment of $(20,900) and interest expense of $(8,276)
resulting in total other expense of $(482,408). Comparatively, for the year ended December 31, 2022, the Company had total other expense
of $0.

 For the years ended December 31, 2023 and 2022,
the Company had a net loss of $(592,071) and $(78,308), respectively.

 For the years ended December 31, 2023 and 2022,
the Company had unrealized loss on available-for-sale securities of $(20,800) and $(39,000), respectively resulting in total comprehensive
loss of $(576,652) and $(117,308) for the respective periods.

 Liquidity and Capital Resources

had a net loss of $(592,071). For the year ended December 31, 2023, the Company incurred amortization expense of $5,932, investment in
Chill N Out Cryotherapy-related party of $20,900, common stock issued for services of $81,600, common stock issued for expenses –
related party of $8,539, accounts payable of $(8,521) resulting in net cash used by operating activities of $(13,347).

 For the year ended December 31, 2022, the Company
had a net loss of $(117,308). For the year ended December 31, 2022, the Company incurred amortization expense of $5,932, investment in
Chill N Out Cryotherapy-related party of $39,000, and accounts payable of $7,724 resulting in net cash used by operating activities of
$(64,652).

 For the years ended December 31, 2023 and 2022,
the Company did not pursue any investing activities.

made repayment of loans – related party of $(110), received proceeds from loans payable – related party of $12,781 resulting
in net cash used in operating activities of $13,347).

 For the year ended December 31, 2022, the Company
received proceeds from loans payable-related party of $41,670 and repayment of loans-related party of $(700) resulting in net cash provided
by financing activities of $40,970.

 The Company merged into BioRegenx, Inc, a Nevada
corporation subsequent to year end. Management intends to raise additional debt or equity financing to fund ongoing operations and for
necessary working capital. However, there is no assurance that such financing plans will be successful or be obtained in amounts sufficient
to meet the Company's needs.

 Notwithstanding, the Company anticipates generating
losses and therefore may be unable to continue operations in the future. The Company anticipates it will require additional capital in
order to develop its business. The Company may use a combination of equity and/or debt instruments or enter into a strategic arrangement
with a third party. Management has yet to find a solution to its funding requirements.

 Going Concern

 Our ability to continue as a going concern is
contingent upon the successful completion of additional financing arrangements and our ability to achieve and maintain profitable operations.

 Therefore, management plans to raise equity capital
to finance the operating and capital requirements of the Company. While the Company is devoting its best efforts to achieve the above
plans, there is no assurance that any such activity will generate funds that will be available for operations. These conditions raise
substantial doubt about the Company's ability to continue as a going concern.

 Significant changes in the number of employees

 We currently have a total of ten employees. We
are dependent upon our officers for our future business development. As our operations expand we anticipate the need to hire additional
employees, consultants and professionals; however, the exact number is not quantifiable at this time.

 Off-Balance Sheet Arrangements

 We do not have any off-balance sheet arrangements
that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues
or expenses, results or operations, liquidity, capital expenditures or capital resources that is material to investors.

 Critical Accounting Policies and Estimates

 Revenue Recognition: The Company recognizes revenue
related to product sales when (i) persuasive evidence of the arrangement exists, (ii) shipment has occurred, (iii) the fee is fixed or
determinable, and (iv) collectability is reasonably assured.

 Recent Pronouncements

 The Company's management has evaluated all the
recently issued accounting pronouncements through the filing date of these financial statements and does not believe that any of these
pronouncements will have a material impact on the Company's current financial position and results of operations.

 ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 Not applicable

 ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 Financial Statements

 For the Year Ended December 31, 2023

 Report of Independent Registered Public Accounting Firm

 Balance Sheets as of December 31, 2023 and 2022

 Statements of Operations for the years ended December 31, 2023 and 2022

 Statement of Changes in Stockholders' (Deficit) Equity for the years ended December 31, 2023 and 2022

 Statements of Cash Flows for years ended December 31, 2023 and 2022

 Notes to the Financial Statements

 Report of Independent Registered Public Accounting
Firm

 To the shareholders and the board of directors
of BioRegenx, Inc.

 Opinion on the Financial Statements

 We have audited the accompanying balance sheets
of BioRegenx, Inc. as of December 31, 2023 and 2022, the related statements of operations, stockholders' equity (deficit), and cash flows
for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the
financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022,
and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted
in the United States.

 Substantial Doubt about the Company's
Ability to Continue as a Going Concern

 The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has
suffered recurring losses from operations and has a significant accumulated deficit. In addition, the Company continues to experience
negative cash flows from operations. These factors raise substantial doubt about the Company's ability to continue as a going concern.
Management's plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that
might result from the outcome of this uncertainty.

 Basis for Opinion

 These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audit. We
are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.

 We conducted our audit in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's
internal control over financial reporting. Accordingly, we express no such opinion.

 Our audit included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 Critical Audit Matter

 Critical audit matters are matters arising
from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee
and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging,
subjective, or complex judgments.

 We determined that there are no critical audit matters

 /S/ BF Borgers CPA PC (PCAOB ID 5041)

 We have served as the Company's auditor since
2020

 Lakewood, CO

 April 10, 2024

 BALANCE SHEETS

 December 31, 2023

 December 31, 2022

 ASSETS

 Current Assets:

 Cash

 $
 –

 $

 Total Current Assets

 –

 Non-Current Assets:

 Domain Name & Website, net of amortization of $ 57,441 and $ 51,509, respectively

 31,540

 37,473

 Investment in Chill N Out Chryotherapy – related party

 21,000

 Total Other Assets

 31,640

 58,473

 Total Assets

 $
 31,640

 $
 59,149

 LIABILITIES & STOCKHOLDERS' DEFICIT

 Current Liabilities:

 Accounts Payable and Accrued Expenses

 $
 28,242

 $
 19,721

 Current Portion Long-Term Debt

 200,000

 4,189

 Loans Payable – Related Party

 25,370

 40,970

 Total Current Liabilities

 253,612

 64,880

 Long-Term Debt

 –

 195,811

 Total Liabilities

 253,612

 260,691

 Stockholders' Deficit:

 Preferred Stock, Series A, $ 0.001 par value, 50,000,000 shares authorized, 5,000,000 shares issued and outstanding

 5,000

 5,000

 Preferred Stock, Series B, $ 0.001 par value, 5,000,000 shares authorized, 4,900,000 shares issued and outstanding

 4,900

 4,900

 Common Stock, $ 0.00 1 par value, 500,000,000 shares authorized, 276,750,406 and 269,745,006 issued and outstanding, respectively

 276,750

 269,745

 Additional Paid in Capital

 3,001,149

 2,436,513

 Accumulated Deficit

 ( 3,509,771
)

 ( 2,917,700
)

 Total Stockholders' Deficit

 ( 221,972
)

 ( 201,542
)

 Total Liabilities and Stockholders' Deficit

 $
 31,640

 $
 59,149

 The accompanying notes are an integral part of these financial statements.

 BIOREGENX, INC. (formerly
FINDIT, INC.)

 STATEMENTS OF OPERATIONS

 For the Years Ended
December 31,

 2023

 2022

 Revenues:

 Findit Services

 $
 22,243

 $
 42,159

 Operating Expenses:

 Advertising and Marketing Expenses

 6,043

 Amortization Expense

 5,932

 5,932

 Consulting Services

 81,600

 –

 Content Writing

 –

 21,750

 General and Administrative Expense

 18,254

 27,647

 Professional Fees

 7,080

 27,928

 Programming Fees

 9,735

 Web Design and Hosting Expense

 18,095

 21,432

 Total Operating Expenses

 131,906

 120,467

 Loss from Operations

 ( 109,663
)

 ( 78,308
)

 Other Expense:

 Loss on conversion of debt – related party

 ( 453,232
)

 –

 Interest Expense

 ( 8,276
)

 –

 Total Other Expense

 ( 461,508
)

 –

 Loss Before Provision for Income Tax

 ( 571,171
)

 ( 78,308
)

 Provision for Income Tax

 –

 –

 Net Loss

 ( 571,171
)

 ( 78,308
)

 Other Comprehensive Loss

 Unrealized loss on available-for-sale securities

 ( 20,900
)

 ( 39,000
)

 Total Comprehensive Loss

 $
 ( 592,071
)

 $
 ( 117,308
)

 Loss Per Share, Basic and Diluted

 $
 ( 0.00
)

 $
 ( 0.00
)

 Weighted Average Shares Outstanding, Basic and Diluted

 276,366,548

 269,745,006

 The accompanying notes are an integral part
of these financial statements.

 STATEMENTS OF CHANGES IN STOCKHOLDERS' (DEFICIT) EQUITY

 For the Year Ended December 31, 2023 and 2022

 Preferred Stock,

 Preferred Stock,
 Series B

 Additional Paid

 Accumulated

 Total Stockholders'

 Shares

 Amount

 Shares

 Amount

 Shares

 Amount

 in Capital

 Deficit

 Equity

 Balance, December 31, 2021

 269,745,006

 $
 269,745

 5,000,000

 $
 5,000

 4,900,000

 $
 4,900

 $
 2,436,513

 $
 ( 2,800,392
)

 $
 ( 84,234
)

 Net Loss

 –

 –

 –

 –

 –

 –

 –

 ( 117,308
)

 ( 117,308
)

 Balance, December 31, 2022

 269,745,006

 269,745

 5,000,000

 5,000

 4,900,000

 4,900

 2,436,513

 ( 2,917,700
)

 ( 201,542
)

 Shares issued for services

 1,000,000

 1,000

 –

 –

 –

 –

 80,600

 –

 81,600

 Shares issued for debt and services – related party

 6,005,400

 6,005

 –

 –

 –

 –

 484,036

 –

 490,041

 Net Loss

 –

 –

 –

 –

 –

 –

 –

 ( 592,071
)

 ( 592,071
)

 Balance, December 31, 2023

 276,750,406

 $
 276,750

 5,000,000

 $
 5,000

 4,900,000

 $
 4,900

 $
 3,001,149

 $
 ( 3,509,771
)

 $
 ( 221,972
)

 The accompanying notes are an integral part
of these financial statements.

 BIOREGENX, INC. (formerly
FINDIT, INC.)

 STATEMENTS OF CASH FLOWS

 For the Years Ended
December 31,

 2023

 2022

 Cash Flow from Operating Activities:

 Net Loss

 $
 ( 592,071
)

 $
 ( 117,308
)

 Adjustments to reconcile net loss to net cash used by operating activities:

 Amortization expense

 5,932

 5,932

 Investment in Chill N Out Cryotherapy – related party

 20,900

 39,000

 Common stock issued for services

 81,600

 –

 Common stock issued for expenses– related party

 8,539

 –

 Loss on conversion of debt – related party

 453,232

 –

 Changes in Operating Assets and Liabilities:

 Accounts payable

 8,521

 7,724

 Deferred revenue

 –

 –

 Net Cash Used by Operating Activities

 ( 13,347
)

 ( 64,652
)

 Cash Flows from Investing Activities

 –

 –

 Cash Flows from Financing Activities

 Repayment of loans – related party

 ( 110
)

 ( 700
)

 Proceeds from loans payable – related party

 12,781

 41,670

 Net Cash Provided by Financing Activities

 12,671

 40,970

 Net Change in Cash

 ( 676
)

 ( 23,682
)

 Cash at Beginning of Year

 24,358

 Cash at End of Year

 $
 –

 $

 Cash Paid During the Period for:

 Interest

 $
 –

 $
 –

 Income Taxes

 $
 –

 $
 –

 Supplemental non-cash disclosure:

 Unrealized loss on available-for-sale securities

 $
 ( 20,900
)

 $
 ( 39,000
)

 Common stock issued debt – related party

 $
 –

 $
 28,270

 The accompanying notes are an integral part
of these financial statements

 NOTES TO THE FINANCIAL STATEMENTS

 DECEMBER 31, 2023

 NOTE 1 – ORGANIZATION & NATURE OF
OPERATIONS

 FINDIT, Inc., "the Company", was organized
on December 23, 1998 as a Nevada Corporation. The Company offers online products and services that consists of content distribution, content
creation, web development, Search Engine Optimization, Social Media, and Social Networking Marketing Campaigns. Products and services
include news and press release distribution, Findit extension domains we call Vanity Keyword URLs, Findit Prime which is a bundled package
of press release distribution, vanity URL, URL submissions into the Findit search engine and social media promoted posts.

 NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING
POLICIES

 Basis of Presentation

 The Company's financial statements have
been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").

 Use of Estimates

 The preparation of financial statements in conformity
with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 Revenue Recognition

 The Company only applies the five-step model to
contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it
transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews
the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct.
The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when
the performance obligation is satisfied or as it is satisfied.

 Intangible Assets

 Intangible assets are amortized over a period
of fifteen years on a straight-line basis and consist principally of the cost to acquire the Company's domain name.

 Cash Equivalents

 The Company considers all highly liquid investments
with a maturity of three months or less when purchased to be cash equivalents. There were no cash equivalents for the years ended December
31, 2023 or 2022.

 Concentration of Credit Risk

 The credit risk for customer accounts is not significant
due to its diverse customer base. Customer accounts typically are collected within a short period of time. The Company maintains its cash
balances in one financial institution located in Atlanta, Georgia. The balances are insured by the Federal Deposit Insurance Corporation
up to $250,000. At December 31, 2023 and 2022, the Company had no uninsured cash balances.

 Fair Value Measurements

 The Company follows paragraph 825-10-50-10 of
the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of
the FASB Accounting Standards Codification ("Paragraph 820-10-35-37") to measure the fair value of its financial instruments.
Paragraph 820-10-35-37 establishes a framework for measuring fair value in accounting principles generally accepted in the United States
of America (U.S. GAAP) and expands disclosures about fair value measurements. To increase consistency and comparability in fair value
measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation
techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices
(unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels
of fair value hierarchy defined by Paragraph 820-10-35-37 are described below:

 Level 1: Quoted market prices available
in active markets for identical assets or liabilities as of the reporting date.

 Level 2: Pricing inputs other than
quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.

 Level 3: Pricing inputs that are generally
unobservable inputs and not corroborated by market data.

 The carrying amount of the Company's financial
assets and liabilities, such as cash, prepaid expenses and accrued expenses approximate their fair value because of the short maturity
of those instruments. The Company's notes payable approximates the fair value of such instruments based upon management's
best estimate of interest rates that would be available to the Company for similar financial arrangements at December 31, 2023. See Note
4 for additional disclosures for the Company's investments measured at fair value.

 Stock-based Compensation

 We account for equity-based transactions with
employees and non-employees under the provisions of FASB ASC Topic 718, "Compensation – Stock Compensation" (Topic
718), which establishes that equity-based payments to employees and non-employees are recorded at the grant date the fair value of
the equity instruments the entity is obligated to issue when the employees and non-employees have rendered the requisite service and satisfied
any other conditions necessary to earn the right to benefit from the instruments. Topic 718 also states that observable market prices
of identical or similar equity or liability instruments in active markets are the best evidence of fair value and, if available, should
be used as the basis for the measurement for equity and liability instruments awarded in these share-based payment transactions. However,
if observable market prices of identical or similar equity or liability instruments are not available, the fair value shall be estimated
by using a valuation technique or model that complies with the measurement objective, as described in FASB ASC Topic 718.

 Income Taxes

 Income taxes are provided for the tax effects
of the transactions reported in the financial statements and consist of taxes currently due plus deferred taxes related primarily
to tax net operating loss carryforwards. The deferred tax assets and liabilities represent the future tax return consequences of these
differences, which will either be taxable or deductible when assets and liabilities are recovered or settled, as well as operating loss
carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years
in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change
in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established against deferred
tax assets when in the judgment of management, it is more likely than not that such deferred tax assets will not become available. Because
the judgment about the level of future taxable income is dependent to a great extent on matters that may, at least in part, be beyond
the Company's control, it is at least reasonably possible that management's judgment about the need for a valuation allowance
for deferred taxes could change in the near term.

 Tax benefits are recognized only for tax positions
that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount
of benefit that is greater than 50 percent likely to be realized upon settlement. A liability for "unrecognized tax benefits"
is recorded for any tax benefits claimed in the Company's tax returns that do not meet these recognition and measurement standards.
As of December 31, 2023, and 2022, no liability for unrecognized tax benefits was required to be reported.

 Net Income (Loss) Per Common Share

 Net income (loss) per common share is computed
pursuant to section 260-10-45 of the FASB Accounting Standards Codification. Basic net income (loss) per common share is computed by dividing
net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per
common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding
shares of common stock during the period. The weighted average number of common shares outstanding and potentially outstanding common
shares assumes that the Company incorporated as of the beginning of the first period presented. There are no potentially dilutive common
shares for the years ended December 31, 2023 and 2022.

 Recently Issued Accounting Pronouncements

 The Company has implemented all new accounting
pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise
disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have
a material impact on its financial position or results of operations.

 NOTE 3 – GOING CONCERN

 The accompanying financial statements have been
prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal
course of business for the foreseeable future. The Company has incurred losses since inception resulting in an accumulated deficit of
$ 3,509,771 as of December 31, 2023, and further losses are anticipated in the development of its business raising substantial doubt about
the Company's ability to continue as a going concern.

 The ability to continue as a going concern is
dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations
and repay its liabilities arising from normal business operations as they come due. Management intends to finance operating costs over
the next twelve months with existing cash on hand, and/or private placement of common stock.

 In order to mitigate the conditions that raise
substantial doubt about our ability to continue as a going concern, the company has exited the CBD oil business which consumed substantial
capital and resources and has streamlined operational costs.

 NOTE 4 – INVESTMENTS

 On November 25, 2020, the Company purchased 1,000,000
shares of the common stock of Chill N Out Cryotherapy at $0.01 per share in exchange for technical services provided. This investment
meets the criteria of level one inputs for which quoted market prices are available in active markets for identical assets or liabilities
as of the reporting date. As of December 31, 2023 and 2022, the shares of Chill N Out Cryotherapy have a reported market value of $ 100
and $ 21,000, respectively. The Company has adjusted the reported amounts for these investments to market value resulting in an unrealized
loss of $ 20,900 and $ 39,000 for the years ended December 31, 2023 and 2022, respectively.

 NOTE 5 – DEBT

 The Company borrowed $ 150,000 utilizing the Small
Business Administration's Economic Injury Disaster Loan Program. The loan is repayable at 3.75% beginning one year after the proceeds
were received which was July 20, 2020. Subsequently Congress has extended the repayment period to one year after the initial date, or
July 20, 2022.

 The Company borrowed $ 50,000 utilizing the Small
Business Administration's Economic Injury Disaster Loan Program. The loan is repayable at 3.75% beginning two years after the proceeds
were received which was July 17, 2021.

 As of December 31, 2023, no payments towards the
balance due and the loan may be considered in default.

 Schedule of debt

 December 31, 2023

 December 31, 2022

 SBA Loan – July 20,2020

 $
 150,000

 $
 150,000

 SBA Loan – July 17,2021

 50,000

 50,000

 Total

 $
 200,000

 $
 200,000

 Less: current portion

 ( 200,000
)

 ( 4,189
)

 Long term portion

 $
 –

 $
 195,811

 NOTE 6 – PREFERRED STOCK

 Series A Preferred Stock

 The Series A Preferred Stock holds a voting weight
of 2,500 common shares, is not entitled to receive dividends and has no liquidation rights.

 Series B Preferred Stock

 The Series B Preferred Stock holds a voting weight
of 1,000 common shares, is not entitled to receive dividends and has no liquidation rights.

 NOTE 7 – COMMON STOCK TRANSACTIONS

 During the years ended December 31, 2023, the
Company issued 1,000,000 shares of common stock for services. The shares were valued at $0.0816, the closing stock price on the date of
grant, for total non-cash compensation expense of $ 81,600.

 See Note 8 for shares issued to a related party.

 NOTE 8 – RELATED PARTY TRANSACTIONS

received a total cash advance from Classworx Inc of $ 2,900. Classworx Inc, has the same management and majority shareholders as the Company.
The advance was for general operating expenses, is non-interest bearing and due on demand. The balance due as of December 31, 2023, is
$ 2,890.

received a total cash advance from Thomas Powers, CEO of $ 28,270. On March 31, 2023, the Company issued 6,005,400 shares of common stock
to Mr. Powers, for $ 28,270 of debt and $ 8,539 for expense reimbursement. The shares were valued at $0.0816, the closing stock price on
the date of grant, resulting in a loss on the issuance of $ 453,232.

received a total cash advance from TransworldNews, Inc. of $ 10,500, $ 700 of which was repaid, for a balance due of $ 9,800 as of December
31, 2022. TransworldNews has the same management and majority shareholders as the Company. The advance was for general operating expenses,
is non-interest bearing and due on demand. The balance due as of December 31, 2023, is $ 9,700.

 During the year ended December 31, 2023, Mr. Powers
advanced the Company $ 12,781 to pay for professional fees. The advanced is non-interest bearing and due on demand.

 NOTE 9 - INCOME TAX

 Deferred taxes are provided on a liability method
whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards and deferred
tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts
of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management,
it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities
are adjusted for the effects of changes in tax laws and rates on the date of enactment. The Company is using the U.S. federal income tax
rate of 21%.

 The provision for Federal income tax consists
of the following December 31:

 Provision for income tax

 2023

 2022

 Federal income tax benefit attributable to:

 Current Operations

 $
 ( 124,000
)

 $
 ( 25,000
)

 Less: valuation allowance

 124,000

 25,000

 Net provision for Federal income taxes

 $
 –

 $
 –

 The cumulative tax effect at the expected rate
of 21% of significant items comprising our net deferred tax amount is as follows:

 Schedule of deferred tax assets

 2023

 2022

 Deferred tax asset attributable to:

 Net operating loss carryover

 $
 ( 737,000
)

 $
 ( 613,000
)

 Less: valuation allowance

 737,000

 613,000

 Net deferred tax asset

 $
 –

 $
 –

 At December 31, 2023, the Company had net operating
loss carry forwards of approximately $ 737,000 may be offset against future taxable income. No tax benefit has been reported in the December
31, 2023 or 2022 financial statements since the potential tax benefit is offset by a valuation allowance of the same amount.

 Due to the change in ownership provisions of the
Tax Reform Act of 1986, net operating loss carry forwards for Federal income tax reporting purposes are subject to annual limitations.
Should a change in ownership occur, net operating loss carry forwards may be limited as to use in future years.

 ASC Topic 740 provides guidance on the accounting
for uncertainty in income taxes recognized in a company's financial statements. Topic 740 requires a company to determine whether
it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position. If
the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial
statements.

 The Company files income tax returns in the U.S.
federal jurisdiction, and various state and local jurisdictions.

 NOTE 10 - SUBSEQUENT EVENTS

 Merger with BioRegenx, Inc.

 The Company filed Articles of Merger effective
March 8, 2024 with the state of Nevada. Pursuant to the Articles of Merger, BioRegenx, Inc, a Nevada corporation was merged into the Registrant
with the Registrant being the surviving company. The name of the Company was changed to BioRegenx, Inc.

 Pursuant to the merger,
all of the issued and outstanding BioRegenx common and preferred shares were exchanged for 851,977,296 common shares and 3,800 Series
A preferred shares of the Company which represented 90.0% of the voting securities of the Company. Concurrently, holder(s) of the Company's
Series A and Series B preferred shares retired all of their Series A and Series B preferred shares back into the treasury. The Series
A and Series B preferred shares represented a voting control of 98.47% of the Company. Simultaneously, the majority shareholders retired
a total of 172,197,602 common shares. The exchange value of Company's stock was the average closing price of Registrant for the
month of November 2022.

 Amendment to Articles of Incorporation

 Effective March 8, 2024, the Company filed an
Amendment to the Articles of Incorporation which increased the authorized common stock to One Billion Five Hundred Thousand (1,500,000,000)
common shares. Additionally, the name of the Company was changed to BioRegenx, Inc.

 Certificate of Designation

 The Company discovered that a Certificate of Designation
was not properly filed in 2013 creating the 5,000,000 Series A preferred shares. Effective March 14, 2024, the Company filed a Certificate
of Designation (and subsequently, a Certificate of Correction) curing the 2013 creation of the Series A preferred shares and ratifying
the issuances of 5,000,000 Series A preferred shares in 2013 which were retired pursuant to the terms of the merger. Each Series A preferred
share has voting rights of 2,500 votes per Series A preferred share.

 Management has evaluated subsequent events pursuant
to the requirements of ASC Topic 855, from the balance sheet date through the date the financial statements were issued and has determined
that there are no other material subsequent events that require disclosure in these financial statements.

 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE

 None

 ITEM 9A. CONTROLS AND PROCEDURES

 Disclosure Controls and Procedures

 Disclosure
controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under the Exchange
Act is recorded, processed, summarized and reported, within the time period specified in the SEC's rules and forms, and that such
information is accumulated and communicated to management, including the CEO and CFO, as appropriate, to allow timely decisions regarding
required disclosures. Our management necessarily applied its judgment in assessing the costs and benefits of such controls and procedures,
which, by their nature, can provide only reasonable assurance regarding management's control objectives.

 Our management,
with the participation of our CEO, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as
of the year ended December 31, 2023. Based upon this evaluation, our CEO concluded that our disclosure controls and procedures were not
effective because of the identification material weaknesses in our internal control over financial reporting as described below.

 Management's
Report on Internal Control Over Financial Reporting

 Our management
is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange
Rule 13a-15(f). Our internal control over financial reporting is a process designed to provide reasonable assurance to our management
and board of directors regarding the reliability of financial reporting and the preparation of the financial statements for external purposes
in accordance with U.S. GAAP.

 Our internal
control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable
detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP and our receipts and expenditures
are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on our
financial statements.

 Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. All internal control systems,
no matter how well designed, have inherent limitations, including the possibility of human error and the circumvention of overriding controls.
Accordingly, even effective internal control over financial reporting can provide only reasonable assurance with respect to financial
statement preparation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may
become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 Our management
assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. In making this assessment, it used
the criteria set forth by the Committee of Sponsoring Organizations of the Tread way Commission ("COSO") in Internal Control-Integrated
Framework (2013). Based on this evaluation, management concluded that our internal control over financial reporting was not effective
as of December 31, 2023. Our CEO concluded we have material weaknesses due to lack of segregation of duties, a limited corporate governance
structure, and a lack of a formal management review process over preparation of financial information. A material weakness is a deficiency,
or a combination of control deficiencies, in internal control over financial reporting such that there is a reasonable possibility that
a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

 Our size
has prevented us from being able to employ sufficient resources to enable us to have an adequate level of supervision and segregation
of duties within our system of internal control. Therefore, while there are some compensating controls in place, it is difficult to ensure
effective segregation of accounting and financial reporting duties. Management reported the following material weaknesses:

 Certain reports that we prepare,
and accounting and reporting conclusions reached in connection with the financial statement preparation process are not subjected to a
formal review process that includes multiple levels of review and are not submitted timely to the Board of Directors for review or approval;
and

 Lack of segregation of duties
in certain accounting and financial reporting processes including the initiation, processing, recording and approval of disbursements.

 Our corporate governance
responsibilities are performed by the Board of Directors, none of whom are independent under applicable standards; we do not have an audit
committee or compensation committee. Our Board of Directors acts primarily by written consent without meetings which results in several
of our corporate governance functions not being performed concurrent (or timely) with the underlying transactions, including evaluation
of the application of accounting principles and disclosures.

 The Company lacks adequate
financial reporting capabilities – Due to the minimal operations and small size of the Company we have not employed individuals
that have the necessary accounting knowledge and expertise to ensure accurate financial reporting under US GAAP.

 The Company lacks appropriate
information technology controls – As of December 31, 2023, the Company retains copies of all financial data and material agreements;
however, there is no formal procedure or evidence of normal backup of the Company's data or off-site storage of data in the event
of theft, misplacement, or loss due to unmitigated factors.

 While we
strive to segregate duties as much as practicable, there is an insufficient volume of transactions at this point in time to justify additional
full-time staff. We may not be able to fully remediate the material weaknesses until we expand operations at which time, we would expect
to hire more staff. We will continue to monitor and assess the costs and benefits of additional staffing.

 We do not
expect that our disclosure controls and procedures will prevent all errors and all instances of fraud. Disclosure controls and procedures,
no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure
controls and procedures are met. Further, the design of disclosure controls and procedures must reflect the fact that there are resource
constraints, and the benefits must be considered relative to their costs. Because of the inherent limitations in all disclosure controls
and procedures, no evaluation of disclosure controls and procedures can provide absolute assurance that we have detected all our control
deficiencies and instances of fraud, if any. The design of disclosure controls and procedures also is based partly on certain assumptions
about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under
all potential future conditions.

 Changes in Internal Control Over Financial
Reporting

 During the year ended December 31, 2023, there
were no changes in our internal controls over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act)
that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.3.
Based upon this evaluation, our CEO concluded that our disclosure controls and procedures were not effective because of the identified
material weaknesses in our internal control over financial reporting as described above.

 ITEM 9B. OTHER INFORMATION

 During the quarter
ended December 31, 2023, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement"
or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

 ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

 The following table sets forth certain information
regarding our current directors and executive officers. Our executive officers serve one-year terms.

 Name

 Age

 Position

 Term

 William Resides

 Chief Executive Officer, Interim Chief Financial Officer, Director

 Robert Doran

 Executive Vice President, Director

 Gary Hennerberg

 Secretary, Director

 Sherri Adams

 Chief Operating Officer, Director

 Suzanne Bird

 Jody Walker

 Gary Kiss

 Thomas Powers

 July 3, 2013

 Officers and Directors

 The following is the biographical information
for the current officers and directors of the Company.

 William Resides

 Mr. Resides is the Chief Executive Officer, Interim
Chief Financial Officer and a Director of the Company. An experienced sales executive and passionate entrepreneur, Mr. Resides is the
Co-founder and Chief Executive Officer of NuLife where he leads a global team of Brand Partners on a mission of redefining health utilizing
the latest in technologies and top of class products in the health and wellness sector. He has served in that role since January 2, 2019.
From October 2012 to January 1, 2019, Mr. Resides has been a managing member of NuLife Ventures LLC. From March 2016 to present, Mr. Resides
has been a managing member of Resides Enterprises, LLC., a management consulting company. In addition, Mr. Resides has served as Vice
President of Business Development for Loop Media Inc, a public company, as well as the Vice President of Business Development for Crypto
Insiders LLC, and Money Clip 360 Inc., developing innovation agendas and digital strategies to move their portfolio of products and services
into online "Hy-bred Direct Sales" model. Before NuLife, Mr. Resides was in Chief Executive roles at AllTech Systems LLC,
Allwired Technologies Inc. and Audio Visions Inc., throughout the '90s until 2011. From 1986 to 1988, Mr. Resides attended Carson
Newman College.

 Robert Doran

 Mr. Doran is the Executive Vice President and
a Director of the Company. Mr. Doran has been the CMO and Co-Founder of NuLife since December 2018 to December 2019 and the Executive
Vice President and Co-Founder of NuLife since January 2020. From March 1995 to present, Mr. Doran has been the Co-Founder of LifePower,
Inc., a management company. From June 1999 to present, Mr. Doran has been the Co-Founder of Energy Network, LLC, a marketing consulting
company From January 2020 to present, Mr. Doran has been the Co-Founder of Traction X39 LLC, a real estate holdings company. Mr. Doran
is a traditional business guy that started in Cable TV at age 14... then graduated into real estate sales and investing. In 1999, after
a few years of mentorship, he and his wife launched their own Magazine, House & Home Magazine, that they grew to over 500,000 readers,
exiting in 2012 with a sale to a large media company.

 Gary Hennerberg

 Gary Hennerberg is the Secretary
and a Director of Company and the Chief Executive Officer for its subsidiary, Microvascular Health Solutions LLC In his career, Mr. Hennerberg
has worked as a consultant to organizations such as the Dow Chemical Company, Assurity Life Insurance, Eli Lilly, AAA, CitiFinancial,
Collin Street Bakery, Sprint, Medical Arts Press, and dozens more. Gary is the writer behind the GlycoCheck and Endocalyx Pro stories
and has developed the financial models and projections for BioRegenx companies. His marketing campaigns increased sales by more than 60%
and have reached an estimated 150 million households globally, with his work translated into Spanish, German, and Japanese. Mr. Hennerberg
is the author of "Crack the Customer Mind Code / Seven Pathways from Head to Heart to YES!" (Morgan James Publishing) 2016;
Author of "Direct Marketing Quantified: The Knowledge is in the Numbers" (Target Marketing Publishing) 2005, and "Spinal
Stenosis and Back Pain Relief Treatments Reviewed" (self-published, 2018). Mr. Hennerberg has been a columnist and webinar presenter
for Target Marketing Magazine and Today @ Target Marketing 1993 – 2016, and a speaker at numerous events. He has taught copywriting
courses for American Writers and Artists since 2004. Prior to 1992, he was Vice President of U.S. Communications Marketing Agency, Vice
President of Direct Marketing for CMF&Z, a Young and Rubicam Advertising Agency, and on the client-side Gary has worked as a Product
Manager and Marketing Manager for several companies. Gary obtained a B.A. Communications from Fort Hays State University in 1978.

 Sherri Adams

 Ms. Adams is Chief Operating Officer and a Director
for the Company. Ms. Adams is a seasoned business leader with extensive experience in managing multi-million-dollar development relationship
portfolios. From 2013 to 2021, she worked as a consultant, specializing in hotel contract negotiations and on-site management for large
corporate events. In 2021, she joined NuLife Sciences, Inc., where she has utilized her expertise in aligning business marketing and development
strategies to forge successful corporate partnerships. Ms. Adams has a proven track record in designing and executing impactful community
programs and events that synergistically combine nonprofit missions with corporate business and philanthropic objectives. As an experienced
corporate director, Ms. Adams has demonstrated a history of success in the health and wellness markets. She has a diverse skill set that
includes prospect research, corporate communications, compliance initiatives, client relations, account management, and marketing strategy.
In 1994, she graduated with a bachelor's degree in education from Indiana University of Pennsylvania.

 Suzanne Bird

 Mrs. Bird is a Director of the Company. From 2006
to present, Mrs. Bird has been the Financial Administrator of the Fertility Center with offices located in Chattanooga and Knoxville,
Tennessee. Mrs. Bird wrote and supported accounting software for the rental/retail industry from 1986 to 1991. In December 1985, Mrs.
Bird received her Bachelor of Science in Computer Science from Southern Adventist University, Collegedale, Tennessee. She is the wife
of Joseph S. Bird, Jr., M.D., co-founder of the Company and NuLife.

 Jody Walker

 Mrs. Walker is a Director of the Company. From
1989 to present, Mrs. Walker has been in private practice as a securities and corporate attorney. Her practice focuses primarily on regulatory
compliance, mergers and acquisitions, public and private offerings with debt and equity securities, blue sky filings and general corporate
matters. Mrs. Walker earned her Juris Doctorate from Hamline University in 1985 focusing on securities and taxation. She earned a Bachelor
of Individualized Studies majoring in international business, french and government from the University of Minnesota in 1982.

 Gary Kiss

 Mr. Kiss
is a Director of the Company. From inception (April 4, 2023) to present, Mr. Kiss has been the Chief Executive Officer of DocSun Biomedical
Holdings, Inc. Upon the acquisition of DocSun Biomedical Holdings Inc. by BioRegenx, Mr. Kiss resigned as Chairman of the Board of Directors
of DocSun Biomedical Holdings, Inc. and accepted his appointment as Director of BioRegenx. Mr. Kiss brings valuable experience in the
fields of biomedicine and medical rejuvenation, with over ten years of industry experience in stem cell services. His expertise is instrumental
in guiding the strategic direction of Docsun Biomedical Holdings Inc.

 Thomas Powers

 Mr. Powers is a Director of the Company. Mr. Powers
has an extensive sales and business development background as well as being a vacation rental property manager himself. Mr. Powers also
founded Abodeca which is a direct booking vacation rental website that is now part of the Resortia family. Mr. Powers has proven success
in many other B2B ventures including the Security Industry, Merchant Services, Point of Sale and SEO consulting with the Company. This
experience combined with first-hand knowledge of online marketing SEO and Social Media along with Vacation Rental Property business and
Real Estate makes him a valuable addition to the team. Mr. Powers is currently, in addition to the Company, a Director of ClassWorx, Inc.

 Involvement in Certain Legal Proceedings.

 Our directors, executive officers and control
persons have not been involved in any of the following events during the past ten years and which is material to an evaluation of the
ability or the integrity of our directors or executive officers:

 1. any bankruptcy petition filed by
or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within
two years prior to that time;

 2. any conviction in a criminal proceeding
or being subject to a pending criminal proceeding (excluding traffic violations and other minor offences);

 3. being subject to any order, judgment,
or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining,
barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities;

 4. being found by a court of competent
jurisdiction (in a civil action), the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or
commodities law, and the judgment has not been reversed, suspended, or vacated;

 5. any judicial or administrative proceedings
resulting from involvement in mail or wire fraud or fraud in connection with any business entity;

 6. Any judicial or administrative proceedings
based on violations of federal or state securities, commodities, banking or insurance laws and regulations, or any settlement to such
actions; and

 7. Any disciplinary sanctions or orders
imposed by a stock, commodities or derivatives exchange or other self-regulatory organization.

 Section 16(a) Beneficial Ownership Reporting Compliance

 Section 16(a) of the Securities Exchange Act of
1934, as amended (the "Exchange Act"), requires our executive officers and directors, and persons who beneficially own more
than ten percent of our common stock, to file initial reports of ownership and reports of changes in ownership with the SEC. Executive
officers, directors and greater than ten percent beneficial owners are required by SEC regulations to furnish us with copies of all Section
16(a) forms they file. Based upon a review of the copies of such forms furnished to us and written representations from our former executive
officers and directors, we believe that as of the date of this report they were not current in their 16(a) reports.

 Board of Directors

 Our board of directors currently consists of eight
members. Our directors serve one-year terms.

 Audit Committee

 The Company does not presently have an Audit Committee.
No qualified financial expert has been hired because the Company is too small to afford such expense.

 Committees and Procedures

 1.
 The Company has no standing audit, nominating and compensation committees of the Board of Directors, or
committees performing similar functions. Members of the Board of Directors act in lieu of committees due to its small size. Now that the
merger has occurred, the Company will move forward to finalize the required committees.

 2.
 The members of the Board who act
as nominating committee are not independent, pursuant to the definition of independence of a national securities exchange registered pursuant
to section 6(a) of the Act (15 U.S.C. 78f(a).

 3.
 The nominating committee has no
policy with regard to the consideration of any director candidates recommended by security holders, but the committee will consider director
candidates recommended by security holders.

 4.
 The basis for the view of the board
of directors that it is appropriate for the Company not to have such a policy is that there is no need to adopt a policy for a small company.

 5.
 The nominating committee will consider
candidates recommended by security holders, and by security holders in submitting such recommendations.

 6.
 There are no specific, minimum qualifications
that the nominating committee believes must be met by a nominee recommended by security holders except to find anyone willing to serve
with a clean background.

 7.
 The nominating committee's process
for identifying and evaluation of nominees for director, including nominees recommended by security holders, is to find qualified persons
willing to serve with a clean backgrounds. There are no differences in the manner in which the nominating committee evaluates nominees
for director based on whether the nominee is recommended by a security holder, or found by the board.

 Code of Ethics

 We have not adopted a Code of Ethics for the Board
and any salaried employees.

 Limitation of Liability of Directors

 Pursuant to the Nevada General Corporation Law,
our Articles of Incorporation exclude personal liability for our Directors for monetary damages based upon any violation of their fiduciary
duties as Directors, except as to liability for any breach of the duty of loyalty, acts or omissions not in good faith or which involve
intentional misconduct or a knowing violation of law, or any transaction from which a Director receives an improper personal benefit.
This exclusion of liability does not limit any right which a Director may have to be indemnified and does not affect any Director's liability
under federal or applicable state securities laws. We have agreed to indemnify our directors against expenses, judgments, and amounts
paid in settlement in connection with any claim against a Director if he acted in good faith and in a manner he believed to be in our
best interests.

 Nevada Anti-Takeover Law and Charter and Bylaw
Provisions

 The anti-takeover provisions of Sections 78.411
through 78.445 of the Nevada Corporation Law apply to the Company. Section 78.438 of the Nevada law prohibits the Company from merging
with or selling more than 5% of our assets or stock to any shareholder who owns or owned more than 10% of any stock or any entity related
to a 10% shareholder for three years after the date on which the shareholder acquired the Company's shares, unless the transaction
is approved by the Company's Board of Directors. The provisions also prohibit the Company from completing any of the transactions described
in the preceding sentence with a 10% shareholder who has held the shares more than three years and its related entities unless the transaction
is approved by our Board of Directors or a majority of our shares, other than shares owned by that 10% shareholder or any related entity.
These provisions could delay, defer or prevent a change in control of the Company.

 ITEM
 11. EXECUTIVE COMPENSATION

 The following table sets forth summary executive
compensation information for the fiscal years ended December 31, 2023 and December 31, 2022.

 Summary Compensation Table

 Name and principal position

 Year

 Salary

 Bonus

 Stock

 awards

 Option Awards

 All other compensation

 Total

 ($)

 ($)

 ($)

 ($)

 ($)

 ($)

 William Resides

 2023

 n/a

 n/a

 n/a

 n/a

 n/a

 n/a

 Chief Executive Officer and

 Interim Chief Financial Officer

 2022

 n/a

 n/a

 n/a

 n/a

 n/a

 n/a

 Robert Doran

 2023

 n/a

 n/a

 n/a

 n/a

 n/a

 n/a

 Executive Vice President

 2022

 n/a

 n/a

 n/a

 n/a

 n/a

 n/a

 Sherri Adams

 2023

 n/a

 n/a

 n/a

 n/a

 n/a

 n/a

 Chief Operating Officer

 2022

 n/a

 n/a

 n/a

 n/a

 n/a

 n/a

 Gary Hennerberg

 2023

 n/a

 n/a

 n/a

 n/a

 n/a

 n/a

 Secretary

 2022

 n/a

 n/a

 n/a

 n/a

 n/a

 n/a

 Ray Firth

 2023

 Former President

 2022

 Thomas Powers

 2023

 (1
)

 Former Chief Executive Officer

 2022

 (1) On March 31, 2023, the
Company issued 6,005,400 shares of common stock to Mr. Powers, for $28,270 of debt and $8,539 for expense reimbursement. The shares
were valued at $0.0816, the closing stock price on the date of grant, resulting in a loss on the issuance of $453,232.

 No compensation has been paid to management by
the Company since inception.

 We do not maintain key-man life insurance for
our executive officer/director. We do not have any long-term compensation plans or stock option plans.

 As of the date hereof, there have been no grants
of stock options to purchase our Common Stock made to the executive officers named in the Summary Compensation Table.

 Stock Option Grants

 We did not grant any stock options to the executive
officers or directors from inception through the fiscal year end December 31, 2023.

 Outstanding Equity Awards

 We did not have any outstanding equity awards
to the executive officers or directors from inception through fiscal year end December 31, 2023.

 Option Exercises

 There were no options exercised by our executive
officers or directors from inception through fiscal year end December 31, 2023.

 Potential Payments upon Termination or Change
in Control

 We have not entered into any compensatory plans
or arrangements with respect to our executive officers, which would in any way result in payments to such officer because of his resignation,
retirement, or other termination of employment with us or our subsidiaries, or any change in control of, or a change in his responsibilities
following a change in control.

 Director Compensation

 We did not pay our directors any compensation
during fiscal years ended December 31, 2023 or December 31, 2022.

 ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

 The following table presents information, to
the best of our knowledge, about the ownership of our common stock on April 11, 2024 relating to those persons known to
beneficially own more than 5% of our capital stock and by our named executive officers and directors.

 Beneficial ownership is determined in accordance
with the rules of the Securities and Exchange Commission and does not necessarily indicate beneficial ownership for any other purpose.
Under these rules, beneficial ownership includes those shares of common stock over which the stockholder has sole or shared voting or
investment power. The percentage ownership of the outstanding common stock, however, is based on the assumption, expressly required by
the rules of the Securities and Exchange Commission, that only the person or entity whose ownership is being reported has converted options
or warrants into shares of the Company's common stock.

 The percentages below are calculated based on
3,800 shares of our Series A preferred stock and 956,630,100 shares of our common stock issued and outstanding. We do not have any outstanding
options, warrants or other securities exercisable for or convertible into shares of our common stock.

 Officers and Directors

 Title of Class

 Amount and Nature

 of Beneficial Ownership

 % of Class

 Voting Power %

 William R. Resides

 20,674,000 - Direct

 2.16

 2.14

 PO Box 21210 Chattanooga, TN 37424

 198,061,145 - Indirect (1)

 20.70

 20.50

 112 - Direct

 2.94

 0.03

 1,008 - Indirect

 26.53

 0.26

 Robert Doran

 1001 Michael Lane, Eagleville PA 19403

 73,800,000 - Indirect(2)

 7.71

 7.64

 400 - Indirect

 10.53

 0.10

 Sherri Adams(4)

 1,000 - Direct

 14816 Surveyor Blvd Addison TX 75001

 0 -Indirect

 Gary Hennerberg

 4,610,000 - Direct

 0.48

 0.48

 5501 Willow Lane Colleyville, TX 76034

 108 - Direct

 2.84

 0.03

 0 -Indirect

 Suzanne Bird

 416,000 - Direct

 0.04

 0.04

 PO Box 28261 Chattanooga, TN 37424

 84,799,264 - Indirect(3)

 8.86

 8.78

 432 - Indirect

 11.37

 0.11

 Jody Walker(5)

 7841 South Garfield Way, Centennial,
CO 80122

 0 -Indirect

 Gary Kiss

 9,349,568 - Direct

 0.98

 0.97

 3197 North Fork Left Fork Road,

 Black
Mountain, NC 28711

 Thomas Powers

 6,005,400 - Direct

 0.63

 0.62

 701 N. Pine Street, Elizabeth PA 37643

 Officers and Directors

 Title of Class

 Amount and Nature

 of Beneficial Ownership

 % of Class

 Voting Power %

 Officers and Directors as a whole (8 persons)

 41,045,968 - Direct

 4.29

 4.25

 356,464,208 - Indirect

 37.26

 36.90

 220 - Direct

 5.79

 0.06

 1,840 - Indirect

 48.42

 0.48

 Other 5% Shareholders

 Wilshire Holding Trust(1)

 197,864,944 - direct

 20.68

 20.48

 William Resides TTEE

 PO Box 2121- Chattanooga, TN 37424

 1,008 - Direct

 26.53

 0.26

 JARA Irrevocable Trust(2)

 73,840,300 - Direct

 7.72

 7.64

 Robert Doran TTEE

 1001 Michael Lane, Eagleville PA 19403

 400 - Direct

 10.53

 0.1

 Libertas Trust(3)

 84,799,264 - Direct

 8.86

 8.78

 Joseph S. Bird Jr./Suzanne Bird Jt TTEES

 PO Box 28261 Chattanooga TN 37424

 432 - Direct

 11.37

 0.11

 RNL Lonepeak Holdings, LLC

 187,447,552 - Direct

 19.60

 19.4

 Robert M Long, member

 7 S. Lone Peak Drive Alpine UT 84004

 1,015 - Direct

 26.71

 0.26

 Hans Vink Beheer BV

 122,619,600 - Direct

 12.82

 12.69

 Hans Vink principal

 Groot Haasdal 36333 AV Schimmert,

 The Netherlands

 617 - Direct

 16.24

 0.16

 (1) William Resides, an officer and
director of the Company is the Trustee of the Wilshire Holding Trust. Additionally, William Resides controls Resides Enterprises LLC
which owns 195,201 common shares.

 (2) Robert Doran, an officer and
director of the Company is the Trustee of the JARA Irrevocable Trust.

 (3) Suzanne Bird, a director of the
Company is a co-Trustee of the Libertas Trust.

 (4) Sherri Adams, an officer and
director of the Company owns 15,840,000 stock options exercisable at $2.10 per common share for an exercise period of five years and
853,328 stock options exerciseable into common stock at $3.00 for an exercise period of five year.

 (5) Jody Walker,
a director of the Company owns 6,880,000 stock options exercisable into common stock at $2.10 per common share for an exercise period
of five years.

 We believe that all persons named have full voting
and investment power with respect to the shares indicated, unless otherwise noted in the table. Under the rules of the Securities and
Exchange Commission, a person (or group of persons) is deemed to be a "beneficial owner" of a security if he or she, directly
or indirectly, has or shares the power to vote or to direct the voting of such security, or the power to dispose of or to direct the disposition
of such security. Accordingly, more than one person may be deemed to be a beneficial owner of the same security. A person is also deemed
to be a beneficial owner of any security, which that person has the right to acquire within 60 days, such as options or warrants to purchase
our common stock.

 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED
TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

received a total cash advance from Classworx Inc of $2,900. Classworx Inc, has the same management and majority shareholders as the Company.
The advance was for general operating expenses, is non-interest bearing and due on demand. The balance due as of December 31, 2023, is
$2,890.

received a total cash advance from Thomas Powers, former CEO and currently, a Director, of $28,270. On March 31, 2023, the Company issued
6,005,400 shares of common stock to Mr. Powers, for $28,270 of debt and $8,539 for expense reimbursement. The shares were valued at $0.0816,
the closing stock price on the date of grant, resulting in a loss on the issuance of $453,232.

received a total cash advance from TransworldNews, Inc. of $10,500, $700 of which was repaid, for a balance due of $9,800 as of December
31, 2022. TransworldNews has the same management and majority shareholders as the Company. The advance was for general operating expenses,
is non-interest bearing and due on demand. The balance due as of December 31, 2023, is $9,700.

 During the year ended December 31, 2023, Mr. Powers
advanced the Company $12,781 to pay for professional fees. The advanced is non-interest bearing and due on demand.

 Our officers and directors, Raymond Firth and
Thomas Powers can be considered promoters of Findit, Inc. in consideration of his participation and managing of the business of the company.

 ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.

 Audit Fees

 The aggregate fees billed for the years ended
December 31, 2023 and 2022 for professional services rendered by BF Borgers CPA, PC (PCAOB # 5041) for the audit of the Company's
annual financial statements and review of the financial statements included in the Company's Form 10-Q or services that are normally
provided by the accountant in connection with statutory and regulatory filings or engagements for the periods ended December 31, 2023
and 2022 were $38,500 and $33,900, respectively.

 Audit related fees

 The aggregate fees billed for the years ended
December 31, 2023 and 2022 for assurance and related services by BF Borgers CPA, P.C. that are reasonably related to the performance of
the audit or review of the Company's financial statements for those fiscal years were included in the above listed were $0 and $0,
respectively.

 Tax Fees

 We incurred aggregate tax fees and expenses from
BF Borgers CPA, P.C. during the years ended December 31, 2023 and 2022 for professional services rendered for tax compliance, tax advice,
and tax planning of $0 and $0, respectively.

 All Other Fees

 The board of directors, acting as the Audit Committee
considered whether, and determined that, the auditor's provision of non-audit services was compatible with maintaining the auditor's independence.
All of the services described above for fiscal year 2022 were approved by the board of directors pursuant to its policies and procedures.

 Audit Committee Policies and Procedures

 We do not have an audit committee; therefore,
our three directors pre-approve all services to be provided to us by our independent auditor. This process involves obtaining (i) a written
description of the proposed services, (ii) the confirmation of our Principal Accounting Officer that the services are compatible with
maintaining specific principles relating to independence, and (iii) confirmation from our securities counsel that the services are not
among those that our independent auditors have been prohibited from performing under SEC rules. In fiscal year ending December 31, 2022,
all fees paid to BF Borgers CPA, P.C. were unanimously pre-approved in accordance with this policy.

 ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 (a)(1) List of Financial statements included in Part II hereof

 Balance Sheets, December 31, 2023 and 2022

 Statements of Operations for the years ended December 31, 2023 and 2022

 Statements of Stockholders' Equity (Deficit) for the years ended December 31, 2023 and 2022

 Statements of Cash Flows for the years ended December 31, 2023 and 2022

 Notes to the Financial Statements

 (a)(2) List of Financial Statement schedules included in Part IV hereof:
None.

 (a)(3) Exhibits

 The following exhibits are included herewith or
incorporated by reference as noted:

 Exhibit No.
 Description

 Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 101.INS*

 101.SCH*
Schema Document

 101.CAL*
Calculation Linkbase Document

 101.DEF*
Definition Linkbase Document

 101.LAB*
Label Linkbase Document

 101.PRE*
Presentation Linkbase Document

and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as
amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject
to liability under these sections.

 Following are a list of exhibits which we previously
filed in other reports which we filed with the SEC, including the Exhibit No., description of the exhibit and the identity of the Report
where the exhibit was filed.

 3.1
 Articles of Incorporation, as currently in effect, incorporated by reference
to Form S-1 filed on March 11, 2021

 3.2
 Bylaws, as currently in effect, incorporated by reference to Form S-1 filed on March 11, 2021

 3.3
 Amendment to the Certificate of Designation, incorporated by reference
to Form 10-K filed on April 4, 2023

 3.4
 Certificate of Amendment to Articles of Incorporation, incorporated by reference to Form 10-K filed on April 4, 2023

 3.5
 Articles of Merger, incorporated by reference to Form 8-K dated 3/8/24 filed on April 1, 2024

 3.6
 Certificate of Amendment filed with the State of Nevada on 3/8/24, incorporated by reference to Form 8-K dated 3/8/24 filed on
 April 1, 2024

 3.7
 Certificate of Designation filed with the State of Nevada on 3/14/24, incorporated by reference to Form 8-K dated 3/8/24 filed on April
1, 2024

 3.8
 Certificate of Correction filed with the State of Nevada, incorporated by reference to Form 8-K dated 3/8/24 filed on April 1, 2024

 99.2
 Press Release dated March 14, 2024, incorporated by reference to Form 8-K dated 3/8/24 filed on April 1, 2024

 SIGNATURES

 Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 BioRegenx, Inc. (formerly Findit, Inc.)

 /s/ William Resides

 By: William Resides

 Chief Executive Officer

 Date: April 11, 2024

 Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated.

 /s/William Resides

 CEO, Interim CFO, Director

 /s/Robert Doran

 Executive Vice President, Director

 /s/Sherri Adams

 COO/Director

 /s/Gary Hennerberg

 Secretary/Director

 /s/Suzanne Bird

 /s/Jody Walker

 /s/Thomas Powers